Steven Kanner
Technik-/Wissenschafts-/F&E-Leiter bei CARIBOU BIOSCIENCES, INC.
Vermögen: 1 Mio $ am 30.04.2024
Aktive Positionen von Steven Kanner
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2017 | - |
Specific Biologics, Inc.
 Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Direktor/Vorstandsmitglied | 10.10.2023 | - |
| Independent Dir/Board Member | 10.10.2023 | - |
Karriereverlauf von Steven Kanner
Ehemalige bekannte Positionen von Steven Kanner
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 19.09.2013 | 01.06.2017 |
Ausbildung von Steven Kanner
| University of California, Berkeley | Undergraduate Degree |
| The University of Miami Leonard M. Miller School of Medicine | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
| Kanada | 2 |
Operativ
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Commercial Services |
- Börse
- Insiders
- Steven Kanner
- Erfahrung
